Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Carboplatin in HRD Advanced Solid Tumors
NCT03209401Phase 1Terminated
- Sponsor
- Georgetown University
- Start
- Oct 2017
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in solid tumor and homologous recombination deficiency (HRD), sponsored by Georgetown University. Started Oct 2017; status: terminated.
02
Drugs
niraparib
03
Conditions
solid tumorhomologous recombination deficiency (HRD)
Beyond the preview
Go deeper on NCT03209401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209401.